A New Drug Target for Drug-Resistant Tumors Has Been Discovered

Small-molecule anticancer drugs such as rapamycin are effective in many cancer types, but these effects are quite limited. In recent years, studies aimed at elucidating the mechanisms of resistance that cancer cells develop against these drugs have increased. In September 2018, Science published a study discovering the mechanism of resistance to rapamycin.
mTOR (mammalian target of rapamycin) is one of the enzymes playing an important role in cell growth.
Abnormal mTOR activity gives rise to many diseases, including cancer, neurodegeneration, type 2 diabetes and obesity. High mTOR activity supports tumor growth. Drugs such as rapamycin bind to mTOR and stop its activity. These drugs have very little effect in cancer cells. Many tumor cells have developed resistance to them. Researchers investigated the relationship between mTOR proteins and drug resistance.
Everolimus (brand name Afinitor), another mTOR inhibitor, had previously received approval, in sequence, for treating kidney cancer, pancreatic neuroendocrine tumors, breast cancer, a rare childhood brain tumor, and gastrointestinal and lung neuroendocrine tumors from the FDA as the approving authority.
According to the Results;
- The previously unknown mTOR3 protein complex was discovered.
- The MTOR3 protein complex was observed to develop resistance to rapamycin in association with the ETV7 protein.
What Does This Study Mean for Us?
- After 25 years of research in which it had remained undetected, a new mTOR3 complex was discovered. This discovery also reveals the cause of resistance to rapamycin.
- A new drug target was also discovered. This may enable next-generation mTOR inhibitors to be developed.
- DRUG RESISTANCE: The Main Factor Complicating Cancer Treatment
Sources
ETV7 is an essential component of a rapamycin-insensitive mTOR complex in cancer.
Science Advances 12 Sep 2018.
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.